Kymera Therapeutics, Inc. (KYMR) Covered Calls

Kymera Therapeutics is a clinical-stage biotechnology company pioneering targeted protein degradation (TPD). It develops oral small molecule degraders to address previously undruggable disease-causing proteins. Kymera focuses on transformative therapies for immunology and oncology, aiming to provide biologics-like efficacy in a convenient pill.

You can sell covered calls on Kymera Therapeutics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for KYMR (prices last updated Tue 4:16 PM ET):

Kymera Therapeutics, Inc. (KYMR) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
91.01 +2.58 50.00 102.50 813K - 6.4
Covered Calls For Kymera Therapeutics, Inc. (KYMR)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Mar 20 90 5.00 97.50 -7.7% -112.4%
Apr 17 90 7.50 95.00 -5.3% -36.5%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Kymera Therapeutics, Inc. (NASDAQ: KYMR), based in Watertown, Massachusetts, is a clinical-stage biopharmaceutical leader specializing in targeted protein degradation (TPD). Unlike traditional inhibitors that only block a protein’s activity, Kymera’s small molecule "degraders" hijack the body’s natural waste-disposal system to completely eliminate disease-causing proteins. This approach allows the company to target "undruggable" proteins that have escaped conventional medicine. Kymera’s primary focus is on developing oral therapies for immune-inflammatory diseases and high-value oncology targets, aiming to combine the potency of injectable biologics with the convenience of a daily pill.

Core Business and Products

  1. KT-621 (STAT6 Degrader): This is a first-in-class oral degrader targeting STAT6, the central driver of Type 2 inflammation. It is currently in Phase 2 clinical trials for atopic dermatitis and asthma, with the potential to compete with major injectable biologics like Dupixent.
  2. IRAK4 Program: Developed in collaboration with Sanofi, this program targets the IRAK4 protein to treat toll-like receptor and IL-1 receptor-mediated inflammation. It is being evaluated for conditions such as hidradenitis suppurativa and atopic dermatitis.
  3. Oncology Pipeline: Kymera is advancing degraders for STAT3 and MDM2. These programs target transcription factors and regulatory proteins that drive tumor growth in liquid and solid cancers, offering a novel mechanism for patients who have failed traditional chemotherapy.
  4. Discovery Engine (Pegasus): The company’s proprietary Pegasus platform uses advanced informatics and structural biology to rapidly identify new degrader candidates. This engine allows Kymera to expand its pipeline into new therapeutic areas with high unmet needs.

Competitive Landscape

Kymera operates at the cutting edge of the biotechnology sector, where it competes with other TPD pioneers and traditional pharmaceutical giants. Its most direct peers in the protein degradation space include Arvinas, Inc. and Nurix Therapeutics. In the broader immunology market, its oral STAT6 degrader faces competition from established biologics produced by companies like Regeneron Pharmaceuticals and Sanofi. Additionally, it overlaps with oncology-focused biotech firms such as Revolution Medicines and C4 Therapeutics. Kymera’s advantage lies in its specific focus on oral immunology degraders, a niche where it currently maintains a first-mover advantage for targets like STAT6.

Strategic Outlook and Innovation

Kymera’s 2026 strategy is centered on advancing its "Oral Immunology First" roadmap. The company is prioritizing the clinical development of KT-621, with major Phase 2b data readouts expected in 2027 that could validate TPD as a superior modality for inflammatory diseases. To support this growth, Kymera maintains a strong balance sheet with approximately $1.6 billion in cash, providing a financial runway through 2029. This capital allows management to aggressively fund multiple mid-stage trials simultaneously while continuing to invest in its early-stage discovery engine for next-generation candidates.

Innovation at Kymera involves expanding the application of its E3 ligase toolbox, which allows the company to tailor degraders for specific tissue types or cell populations. This precision medicine approach aims to improve safety profiles by sparing healthy tissues while maximizing the degradation of harmful proteins. Furthermore, the company is leveraging its strategic alliances with Sanofi and Gilead Sciences to accelerate the commercialization of its oncology and immunology assets. By integrating AI-driven structural modeling into the Pegasus platform, Kymera seeks to shorten the time from target identification to clinical entry, maintaining its position as a leader in the TPD revolution.